The Bio/Pharma Beat

    October 2019
    We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from September 2019, including:
    • An analysis of early entry triggers in an ANDA settlement agreement
    • The patent venue statute does not require a nexus between the “established place of business” and the alleged acts of infringement
    • The dismissal of “sham” litigation antitrust counterclaims